Flowonix

Flowonix operates in a specialized segment of medical devices: implantable systems that deliver medication into the intrathecal space for chronic neurological disorders and pain. Its core product, the Prometra Programmable Infusion Pump System, competes for clinical adoption against larger neuromodulation and drug-delivery portfolios from companies such as Medtronic and B. Braun, while also serving a narrower use case than general infusion-device vendors. Flowonix’s differentiation is centered on targeted spinal delivery and its Precision Dosing System, which is designed for accurate micro-dosing and reduced sensitivity to reservoir volume, temperature, and pressure. The company also highlights a 10-year battery life, a 20 ml reservoir, 96.8% dosing accuracy, and a sutureless catheter connection with redundant locking features. Its $67 million cumulative financing and private status indicate a venture-backed commercial medical-device profile rather than the scale of a diversified strategic manufacturer. The available profile does not identify direct peer companies by name or provide current revenue, market share, reimbursement, or procedure-volume metrics.

Flowonix’s growth trajectory shows a long product-development and financing cycle typical of an implantable medical-device company. Founded in 2005, it raised $25 million in a 2012 venture round, followed by $20 million of venture financing and $15 million of debt financing on Nov 11, 2014. Additional debt financing of $5 million arrived on Jun 2, 2016, and a further $2 million venture round was recorded on Sep 19, 2018, bringing cumulative structured funding to $67 million. Product development progressed from the Prometra programmable pump to the Maestro ProView Platform, announced on May 22, 2018, with a focus on programming assurance and clinician usability. A reported $33 million financing transaction with SWK Holdings in 2021 suggests continued capital support, although it is not represented as one of the five structured rounds. Steve Adler’s listed CEO start date of May 1, 2020 marks a leadership transition after the 2016 CEO appointment announcement.